Key Points
- Dianthus Therapeutics EVP Simrat Randhawa sold 26,530 shares on June 1 at an average price of $90.62, generating about $2.4 million in proceeds. After the sale, Randhawa’s stake fell to 4,000 shares, an 86.9% drop in ownership.
- The insider sale follows a prior transaction in March, when Randhawa sold 33,830 shares at an average price of $81.48 for roughly $2.76 million.
- Despite the insider selling, analysts remain broadly positive on DNTH, with an average rating of Buy and an average price target of $117.82, while the stock recently traded at $81.57.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the sale, the executive vice president directly owned 4,000 shares of the company's stock, valued at $362,480. This trade represents a 86.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Simrat Randhawa also recently made the following trade(s):
- On Thursday, March 12th, Simrat Randhawa sold 33,830 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $81.48, for a total value of $2,756,468.40.
Dianthus Therapeutics Price Performance
Shares of NASDAQ DNTH opened at $81.57 on Wednesday. The company has a market capitalization of $4.46 billion, a price-to-earnings ratio of -19.75 and a beta of 1.18. The business has a 50-day moving average of $86.99 and a two-hundred day moving average of $62.62. Dianthus Therapeutics, Inc. has a 1 year low of $16.64 and a 1 year high of $96.50.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.22. The company had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. As a group, equities research analysts expect that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of analysts have issued reports on DNTH shares. Robert W. Baird lifted their price target on Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an "outperform" rating in a report on Tuesday, March 10th. Jefferies Financial Group set a $98.00 price target on Dianthus Therapeutics and gave the stock a "buy" rating in a report on Monday, March 9th. William Blair reiterated an "outperform" rating on shares of Dianthus Therapeutics in a research report on Monday, March 16th. Oppenheimer lifted their target price on Dianthus Therapeutics to $145.00 and gave the stock an "outperform" rating in a research report on Monday, March 9th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Dianthus Therapeutics in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $117.82.
Read Our Latest Research Report on DNTH
Institutional Trading of Dianthus Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in DNTH. Raymond James Financial Inc. acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth about $27,000. First Horizon Corp acquired a new stake in shares of Dianthus Therapeutics during the first quarter worth about $32,000. Caitong International Asset Management Co. Ltd acquired a new position in Dianthus Therapeutics in the 4th quarter valued at about $40,000. Russell Investments Group Ltd. acquired a new position in Dianthus Therapeutics in the 3rd quarter valued at about $64,000. Finally, Tower Research Capital LLC TRC increased its position in Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock valued at $80,000 after acquiring an additional 3,317 shares during the period. Institutional investors and hedge funds own 47.53% of the company's stock.
About Dianthus Therapeutics
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
